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Abstract 
Introduction: The endocrine system is responsible for hormonal secretion and is closely related to the central ner-
vous system, as it diversifies its functions through the hypothalamus and pituitary glands. It controls physiological 
processes and maintains homeostasis. The neuroendocrine system is responsible for adaptation to environmental 
changes. Therefore, in dentistry, it is important to be aware of the risks and difficulties that may arise during the 
dental management of patients with endocrine disorders, and that visits to the dental clinics often represent a 
stressful situation. 
Objectives: To review the literature on oral manifestations and dental management in patients with endocrine disor-
ders (disorders of the thyroid, parathyroid and adrenal glands). 
Material and Methods: For the literature review, we carried out a search in Pubmed / Medline database using limits 
and keywords according to the controlled vocabulary “Medical Subject Headings” (MeSH). We obtained a total of 
19 articles (ten literature reviews, one case-control study, and eight clinical case series). 
Results and discussion: We describe the most common oral manifestations in patients with endocrine disorders and 
the special dental management that should be carried out on these patients.
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Introduction 
The endocrine system is responsible for hormonal secre-
tion and is closely related to the central nervous system, 
as it diversifies its functions through the hypothalamus 
and pituitary. It controls physiological processes and 
maintains homeostasis. The neuroendocrine system is 
responsible for adaptation to environmental changes. 
Also, a function of the nervous system is to provide a 
correct organic response. Its response may be primary, 
with the release of neurotransmitters, or if the stimulus 
prevails, the endocrine system secretes hormones. This 
is especially important in dentistry because many of the 
patients attending the dental clinics face stressful situa-
tions (1). Awareness is therefore necessary of the risks 
and difficulties that may arise during the dental manage-
ment of patients with endocrine disorders and the most 
common oral manifestations.
Objetives
The aim of this article was to perform a literature review 
about: 
1. Oral manifestations in patients with endocrine di-
sorders (disorders of the thyroid, parathyroid and 
adrenal glands). 
2. Dental management of patients with endocrine 
disorders (disorders of the thyroid, parathyroid and 
adrenal glands). 
Materials and methods
For the literature review, we carried out a literature 
search in Pubmed / Medline database using the following 
words according to the controlled vocabulary (MeSH): 
“dental management”, “oral manifestations”, “hyper-
thyroidism”, “hypothyroidism”, “hyperparathyroidism” 
“primary hyperparathyroidism”, “secondary hyperpara-
thyroidism”, “hypoparathyroidism”, “Addison’s disea-
se”, “primary adrenocortical insufficiency”, “Cushing’s 
syndrome”, “adrenocortical hyperfunction”.  The limits 
used for the search were:  articles in English or Spanish 
and articles published within the last 10 years.   We re-
viewed a total of 19 articles of which ten were literature 
reviews, one case-control study and eight clinical case 
series.
Results
Oral manifestations and dental management of patients 
with thyroid gland disorders
The thyroid gland secretes three hormones: thyroxine 
(T4), triiodothyronine (T3) and calcitonin. T4 and T3 
are hormones that affect metabolic processes throug-
hout the body and are involved in oxygen use. Thyroid-
stimulating hormone (TSH or thyrotropin), produced 
by the pituitary gland, regulates the secretion of thyroid 
hormones (T4 and T3) through a negative feedback 
mechanism. Calcitonin is involved, with parathyroid 
hormone and vitamin D, in regulating serum calcium 
and phosphorus levels and in the skeletal remodeling. 
Thyroid hormones influence the growth and maturation 
of tissues, energy metabolism and turnover of both cells 
and nutrients (2,3). 
Hyperthyroidism• 
Hyperthyroidism or thyrotoxicosis is defined by a de-
crease in thyroid hormone production and thyroid gland 
function. It is caused by ectopic thyroid tissue, toxic 
thyroid adenoma, toxic multinodular goiter, subacute 
thyroiditis, factitious thyrotoxicosis and Graves’ disease 
and diffuse toxic goiter, being the most common cause 
of hyperthyroidism (2,4).
Hyperthyroidism can have clinical manifestations at 
gastrointestinal levels (weight loss, increased appetite, 
nausea and vomiting), in hair, skin and nails (thin and 
brittle hair, soft nails, warm and moist skin, increased 
skin pigmentation and heat intolerance). In the hands 
(palmar erythema, fine tremor, sweating and clubbing). 
At neuromuscular levels (fatigue, atrophy, weakness, 
muscle fatigue and pain). At cardiovascular levels (ta-
chycardia, palpitations, systolic hypertension and dysp-
nea). At psychological levels (anxiety, nervousness, 
irritability, insomnia, impaired concentration and redu-
ced stress threshold) and in ocular level (bilateral exo-
phthalmos, ptosis, periorbital edema, retraction of the 
upper and lower eyelid due to muscle contracture and 
conjunctival injection) (2,4).
We find oral manifestations such as (2,3) (Table 1): 
ORAL MANIFESTATIONS OF PATIENTS WITH THYROID GLAND DISORDERS
HYPERTHYROIDISM HYPOTHYROIDISM
1. Accelerated dental eruption in children
2. Maxillary or mandibular osteoporosis
3. Enlargement of extraglandular thyroid tissue 
(mainly in the lateral posterior tongue)
4. Increased susceptibility to caries 
5. Periodontal disease
6. Burning mouth syndrome
7. Development of connective-tissue diseases like 
Sjögren’s syndrom or systemic lupus erythematosus
1. Delayed eruption
2. Enamel hypoplasia in both dentitions, (being less 
intense in the permanent dentition)
3. Anterior open bite
4. Macroglossia
5. Micrognathia
6. Thick lips
7. Dysgeusia
8. Mouth breathing
Table 1. Oral manifestations of patients with thyroid gland disorders. 
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accelerated dental eruption in children, maxillary or 
mandibular osteoporosis, enlargement of extraglandu-
lar thyroid tissue (mainly in lateral posterior tongue), 
increased susceptibility to caries and periodontal disease 
(possibly because these patients feel the need to consu-
me higher quantities of sugar to meet their physical re-
quirements), burning mouth syndrome and development 
of connective-tissue diseases such as Sjögren’s syndro-
me or systemic lupus erythematosus.
Treatment of patients with thyrotoxicosis may involve 
antithyroid agents (propylthiouracil, carbimazole, and 
methimazole) which block hormone synthesis; iopanoic 
acid and ipodate sodium that are inhibitors of the peri-
pheral conversion of T4 to T3; beta-blockers (propano-
lol) that slow the adrenergic activity and eliminate the 
tachycardia, anxiety, nervousness, tremors and swea-
ting;  glucocorticosteroids, such as dexamethasone, that 
decrease the secretion of thyroid hormone and iodine 
that inhibits the release of preformed hormone (2,4).
Dental management of the patient with hyperthyroi-• 
dism
Before dental treatment is planned, we must carry out a 
detailed general clinical history, and a consultation with 
the specialist is recommended, to discuss the overall 
condition of the patient. At the time of the treatment we 
must consider several aspects:
In controlled patients, we will carry out the same den-1. 
tal management as in healthy patients. We must avoid 
severe stress situations and the spread of infectious 
foci (3).
In uncontrolled cases, we must take the same precau-2. 
tionary measures as in controlled patients. We must 
restrict the use of epinephrine or other pressor amines 
in local anesthetics of the retraction cords because the 
myocardium of these patients is sensitive to adrena-
line and may unleash arrhythmias, palpitations and 
chest pain (2,3,5). We must avoid surgical procedures 
because surgery, presence of acute oral infection and 
severe stress may precipitate thyroid storm crisis. If 
an emergency dental treatment is required, consul-
tation with the patient’s endocrinologist is advisa-
ble because a conservative treatment is often prefe-
rable. Treatment should be discontinued if signs or 
symptoms of a thyrotoxic crisis develop, and access 
to emergency medical services should be available. 
These symptoms include tachycardia, irregular pulse, 
sweating, hypertension, tremor, nausea, vomiting, ab-
dominal pain and coma (2,3). 
People who have hyperthyroidism and are treated 3. 
with propylthiouracil must be monitored for possible 
agranulocytosis, hypoproteinemia or bleeding, and 
a complete blood count including prothrombin time 
before performing any invasive procedures is usually 
recommended (3). 
These patients are susceptible to central nervous sys-4. 
tem depressant drugs such as barbiturates (3).
In these patients proper analgesia is indicated and 5. 
nonsteroidal anti-inflammatory drugs (NSAIDs) and 
aspirin should be used with caution (3).
Hypothyroidism• 
Hypothyroidism is defined by a deficiency of the thyroid 
hormone. It can be acquired or by congenital defects. 
When it is present in infancy, it is manifested as creti-
nism and if it occurs in adults (especially in middle-aged 
women) it is known as myxedema (3,4,6,7). 
Characteristic signs of cretinism include mental retarda-
tion, developmental and growth delay, marked dispro-
portion between the head and body (wide head), lack 
of muscle tone, overweight, less expressive face with a 
broad and flat nose, hypertelorism, short neck and thick, 
pale, dry and wrinkled skin. Myxedema is characteri-
zed by widespread metabolic slow-down, depression, 
overweight, diminished cardiac output and respiratory 
rate, decreased pulse, generalized edema (especially in 
face and extremities), hoarseness because the edema 
affects to vocal cords, sinus bradycardia, swollen nose, 
ears and lips, thickened and dry skin, scalp brittleness, 
thin or absent eyebrows and decreased sweating. Gene-
ralized edema can affect the tongue causing difficulty 
speaking and swallowing and serrated tongue (3,4,6,7).
Common oral findings in hypothyroidism include (3) 
(Table 1): delayed tooth eruption, enamel hypoplasia in 
both dentitions, being less intense in the permanent den-
tition, micrognathia, open bite due to lack of condylar 
and mandibular growth, macroglossia, thick lips, dys-
geusia and mouth breathing. 
Patients with hypothyroidism are treated with synthetic 
preparations containing sodium liothyronine, sodium le-
vothyroixin or 1-throixine.  (3,7). 
 Hormone replacement therapy based on thyroid hormo-
nes can be prescribed in cases of severe deficiency of 
thyroid hormones.
Dental management of the patient with hypothyroi-• 
dism
Consulting the patients’ physician and carrying out a de-
tailed general clinical history before performing dental 
treatment is indicated (3,7).
In controlled patients we must avoid oral infection 1. 
(3,7). 
In uncontrolled patients, oral infection, central ner-2. 
vous depressants such as narcotics and barbiturates 
should be avoided because they may cause an exag-
gerated response. In controlled patients, these drugs 
should be used sparingly, with a reduced dosage. The 
presence of oral infection, central nervous depressants 
and surgical procedures can precipitate a myxedema-
tous coma. Surgery procedures should also be avoi-
ded in these patients. Myxedematous coma includes 
hypothermia, bradycardia, severe hypotension and 
epileptic seizure. If that happens, dental treatment 
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should be discontinued and access to emergency me-
dical services should be available (3,7).
Drug interactions of 1-thyroxine include (3):3. 
- Metabolism increase using phenytoin, rifampin and 
carbamazepine.
- Absorption is impaired when iron sulfate, sucralfate 
and aluminum hydroxide are used. 
- Concomitant use of tricyclic antidepressants eleva-
tes 1-thyroxine levels. 
These patients are susceptible to cardiovascular di-4. 
sease, therefore they may be on anticoagulation the-
rapy. Before dental treatment is carried out, a com-
plete blood count is required to evaluate coagulation 
factors. We must avoid the use of epinephrine in local 
anesthetics or retraction cords. Antibiotic prophylaxis 
must be assessed in valvular pathology and atrial fi-
brillation (3).
Oral manifestations and dental management of patients 
with parathyroid glands disorders
Parathyroid glands secret parathyroid hormone (PTH) 
involved in regulating the metabolism of calcium and 
phosphorus. PTH plays an important role in tooth deve-
lopment and bone mineralization and increases bone re-
sorption. In the kidneys, it stimulates formation of active 
metabolite of vitamin D, which promotes the intestinal 
absorption of calcium and decreases renal reabsorption 
of phosphate.
Hyperparathyroidism• 
Hyperparathyroidism (HPT) is characterized by hyper-
secretion of parathyroid hormone which occurs in three 
categories (8-11):
- Primary: occurs with a hyperfunction of one or more 
parathyroids, usually caused by a tumour (adenoma in 
85% of all cases) or hyperplasia of the gland that pro-
duces an increase in PTH secretion resulting in hyper-
calcemia and hypophosthamia. 
- Secondary: normally related to patients with intestinal 
malabsorption syndrome or chronic renal failure, oc-
curring in a decrease of vitamin D production or with 
hypocalcemia causing the glands to produce a high 
quantity of PTH. There is also hyperphosphatemia. 
The PTH-related signs are brown tumors and osteitis 
fibrosa cystica, which is referred as renal osteodystro-
phy or Von Recklinghausen’s disease. 
- Tertiary: is an uncommon condition, affecting up to 8 
% of patients with secondary HPT after a successful 
renal transplant. It occurs when the parathyroids ac-
tivity becomes autonomous and excessive, leading to 
hypercalcemia (8).
The diagnosis of HPT is suspected by an increase in 
serum calcium and it is confirmed by the increase in PTH 
(12). One of the main clinical manifestations of hyper-
parathyroidism is bone disease. The ribs, clavicles, pel-
vic girdle and mandible are the bones most involved (9). 
In the oral cavity, the most common clinical manifes-
tations of  HPT are brown tumor, loss of bone density, 
weak teeth, malocclusions, soft tissue calcifications 
and dental abnormalities such  development defects, 
alterations in dental eruption and widened pulp cham-
bers (9) (Table 2).
Brown tumor presents itself as a friable red-brown 
mass. Its name is due to color that it takes from the 
haemorrhagic infiltrates and haemosiderin deposits 
that are often found inside. Brown tumor presents as 
osteolytic lesion that develops due to changes in bone 
metabolism caused by high serum concentration of 
PTH. It is mainly due to secondary HPT in patients 
with renal insufficiency, but it has also been described 
as a rare manifestation of calcium malabsorption and 
some forms of osteomalacia. Nowadays, brown tumor 
is an extremely rare manifestation of primary HPT; in 
these cases it is usually a result of the overproduction 
of the parathyroid hormone by a parathyroid tumor 
(single adenoma, 2 or more adenomas or carcinoma). 
Mandible involvement is common, especially in the 
area of premolars and molars, and it is rare in maxilla. 
ORAL MANIFESTATIONS OF PATIENTS WITH PARATHYROID GLAND DISORDERS
HYPERPARATHYROIDISM HYPOPARATHYROIDISM
1. Dental abnormalities:
- Widened pulp chambers
- Development defects
- Alterations in dental eruption
- Weak teeth
- Maloclussions
2. Brown tumor
3. Loss of bone density 
4. Soft tissue calcifications
1. Dental abnormalities:
- Enamel hypoplasia in horizontal lines
-  Poorly calcified dentin
 - Widened pulp chambers
- Dental pulp calcifications
- Shortened roots
- Hypodontia
- Delay or cessation of dental develop-
ment
2. Mandibular tori
3. Chronic candidiasis
4. Paresthesia of the tongue or lips 
5. Alteration in facial muscles
Table 2. Oral manifestations of patient with parathyroid gland disorders.
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Radiographically, lesions are characterized as well-de-
fined radiolucent areas, uni or multilocular. As charac-
teristic radiographic findings we can find a widespread 
loss of the lamina dura, and changes in the pattern of 
the trabecular bone of the jaws. Long-term injures 
commonly produce a significant expansion of cortical, 
root resorption and displacement of roots can appear. 
Histologically, it is characterized by an abundant es-
troma, consisting of bundles of spindle or oval cells, 
and several multinucleated osteoclast-like giant cells. 
Calcified material can be found, as well as areas with 
extravastion of red blood cells and pigmentation by 
haemosiderin. These findings are not pathognomonic, 
making it necessary to perform a differential diagno-
sis with other lesions such as an aneurismal bone cyst, 
cherubism and central giant cell granuloma; being the 
presence of this lesion together with a history of HPT 
which confirms the diagnosis of brown tumor.  The 
treatment of HPT is the first step in the management 
of the brown tumor, as spontaneous regression of the 
lesion often occurs. However, several cases of brown 
tumor that did not disappear or even grew after nor-
malization of HPT level have been reported. In these 
cases brown tumor resection should be the preferred 
treatment (8,9,13-15).
Dental management of the patient with hyperpara-• 
thyroidism
The clinical management of these patients does not re-
quire any special consideration. We should know that 
there is a higher risk of bone fracture, so we must take 
precaution in surgical treatments. On the other hand, it 
is important to recognize the presence of brown tumour 
and to perform a correct differential diagnosis so as not 
to conduct an inadequate treatment. 
Hypoparathyroidism• 
Hypoparathyroidism is a metabolic disorder characteri-
zed by hypocalcemia and hypophosphatemia due to a 
deficiency or absence of parathyroid hormone secretion. 
It may also develop as an isolated entity of unknown 
etiology (idiopathic hypoparathyroidism), or in combi-
nation with other disorders such as autoimmune diseases 
or developmental defects (16).
Hypoparathyroidism can cause hypocalcemia with con-
sequent paresthesias, tetany and seizures. Disorders of 
ectodermal tissues are also common in these patients. 
These disorders include alopecia, scaling of the skin, de-
formities of the nails and dental abnormalities such as 
enamel hypoplasia in horizontal lines, poorly calcified 
dentin, widened pulp chambers, dental pulp calcifica-
tions, shortened roots , hypodontia and mandibular tori 
as PTH affects rate of eruption, formation of the matrix 
and calcification.  A delay or cessation of dental growth 
and development, chronic candidiasis of the oral mucosa 
and nail, paresthesia of the tongue or lips and alteration 
of the facial muscles can occur (16) (Table 2).  
This pathology is diagnosed on the basis of measure-
ments of serum calcium and parathyroid hormone le-
vels. The main treatments available for these patients is 
vitamin D or its analogues, calcium salts and drugs that 
increase renal tubular resorption of calcium, to obtain 
adequate, but low, normal serum calcium levels (16).
Dental management of the patient with hypopara-• 
thyroidism
These patients have more susceptibility to caries becau-
se of dental anomalies. Dental management will be the 
prevention of caries with periodic reviews, advice regar-
ding diet and oral hygiene instructions. Before perfor-
ming dental treatment, serum calcium levels should be 
determined. They must be above 8mg/100ml to prevent 
cardiac arrhythmias, seizures, laryngospasms or bron-
chospasms.
Oral manifestations and dental management of the pa-
tient with adrenal glands disorders
The adrenal glands are located on the upper pole of each 
kidney. They are composed of an internal or core por-
tion (the adrenal medulla), which produce adrenaline, 
noradrenaline, dopamine and progesterone; and an outer 
portion or cortex, which is in turn responsible for the
production of steroid hormones, such as: glucocorticoids 
(cortisol and cortisone), mineralocorticoids (aldosterone 
and 18-deoxycorticosterone), and androgens (dehydroe-
piandrosterone). The cortex has three layers: glomerular 
or external, where mineralocorticoids are released, the 
fascicular or intermediate, where glucocorticoids are 
produced and reticular or internal where androgens are 
secreted (1).
Regarding the role of substances that are secreted by the 
cortex, cortisol is involved in the mechanisms of adapta-
tion of the organism to stress maintaining homeostasis; 
it has anti-inflammatory and immunosuppressive effect, 
it is responsible for mobilizing fatty acids from adipose 
tissue, it maintains vascular reactivity, it promotes the 
liver’s protein synthesis via neoglycogenesis, it increa-
ses gycemia, it inhibits bone formation and delays hea-
ling.
Corticosteroid production and release from the adrenal 
cortex is in turn regulated by adrenocorticotropic hor-
mone (ACTH), which is synthesized and secreted in the 
anterior hypophysis (adenohypophysis).  In accordance 
to the circulating glucocorticoid concentrations, a self-
regulating or negative feedback mechanism is establis-
hed at hypothalamic and hypophyseal level. ACTH is 
in turn controlled by a series of factors such as cortico-
tropin release hormone (CRH), which is secreted by the 
hypothalamus, and by circadian rhythms (waking-sleep 
cycle), with cyclic variations in the plasma cortisol con-
centrations in the course of the 24-hour day, being maxi-
mum early in the morning and minimum at evening.  Ba-
sal cortisol secretion in turn gradually increases with age, 
and an association moreover exists between high basal 
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cortisol concentrations and a reduction in specific cogni-
tive functions. Aldosterone is necessary for maintaining 
sodium and extracellular fluid balance, resulting in re-
sorption of sodium in exchange with the potasium and 
hydrogen ions in the distal tubule of the nephron and in 
other tissues such as salivary glands and colon. It makes 
up to renin-angiotensin-aldosterone axis. Kidneys, in 
response to low blood volume, real or perceived (heart 
failure), secrete an enzyme called rennin, which acts in 
the general circulation on angiotensinogen produced by 
the liver and converts it into angiotensin I. Angiotensin 
I, under the action of the angiotensin converting enzyme 
(ACE), converts it in angiotensin II. Angiotensin II is 
a potent arteriolar vasoconstrictor and the primary re-
gulator of aldosterone secretion, which maintains blood 
volume by retaining sodium (1).
Addison’s Disease • 
In Addison’s disease or primary adrenal insufficiency 
exists a deficiency in the secretion of glucocorticoid and 
mineralocorticoid hormones by the adrenal cortex. It is 
associated with idiopathic, surgical, or infectious des-
truction or tumor of parenchyma of the adrenal gland or 
infiltration of the cortex by sarcoidosis, tuberculosis or 
amyloidosis (1).
Cortisol deficiency clinically manifests as hypoglyce-
mia, hypotension, asthenia, muscle weakness, anorexia, 
nausea, weight loss and diminished resistance to infec-
tions and stress. 
Characteristic melanic pigmentation may develop as a 
consequence of cessation of inhibition at hypophyseal 
level, with simultaneous increments of both ACTH and 
melanocyte stimulating hormone (MSH). When this ha-
ppens, the skin darkens in regions such as the elbows, 
folds of the hands or areolas of the breasts. The oral mu-
cosa can in turn develop black-bluish plaques, mainly 
affecting buccal mucosa but it can also be seen on the 
gums, palate, tongue and lips. The lack of aldosterone 
leads to sodium and liquid depletion with increased diu-
resis and secondary dehydration and hypotension (1). 
Dental management of the patient with Addison’s • 
disease
Most of these patients are treated with corticosteroids. 
We can distinguish different stages of adrenal suppres-
sion, where we can find the patient undergoing corticos-
teroid therapy (1):
- Stage I: doses of corticosteroids do not produce adrenal 
suppression.
- Stage II: the glucocorticois in blood inhibit the hy-
potalamic-hypophyseal-adrenal axis, and the body 
stops producing cortisol physiologically. This stage is 
therefore characterized by adrenocortical suppression, 
though the administered corticoid dose is still insuf-
ficient to cover the organic needs in the event of stress-
inducing situations. 
- Stage III:  the administered corticoid dose is sufficient-
ly high to continue suppressing the adrenal cortex but 
also to cover the body needs in the event of stress.  
This is interesting when we perform dental treatment 
because according to the stage in which the patient is, 
supplementation of corticosteroids may or not be neces-
sary (1, 17):
- Patients with low-dose corticotherapy (LDC) (< 30mg 
of hydrocortisone/day): 
Patients with a history of regular corticoid use: no 1. 
supplementing is required either for routine pro-
cedures, nor surgical treatments because with this 
dose of corticosteroid, adrenal suppresion does not 
occur. 
Patients presently using corticoids: no supplemen-2. 
ting required.
- Patients with high-dose corticotherapy (HDC) (> 40 
mg of hydrocortisone/day):
Patient with a history of regular use of HDC for 1. 
short periods (less than one month): the adre-
nal suppression is transient, recovering the stress 
response within 14 days after cessation of ste-
roids. Therefore, for routine dental procedures, 
surgical procedures, very extensive treatments 
and in highly anxious patients we must consider: 
 Those who have discontinued corticosteroid 
treatment less than 14 days ago will require a 
daily maintenance dose on the day of treatment. 
    If more than 14 days: no supplementing will be 
required.
Patients with a history of regular use of HDC for 2. 
more than one month: no established regimen.
Patients presently using HDC for one month or 3. 
more: no supplementing required.  
- Patients presently using 30-40 mg of hydrocortisone/
day:
If the patient is highly anxious or lengthy dental 
treatment or surgery procedure is to be performed, we 
must double the daily dose on the day of treatment. If 
postoperative pain is expected, we should also double 
the daily dose on the first postoperative day.  
- Patients receiving corticotherapy on alternate days for 
at least 30 days: 
On the non-corticoid days, no supplementing is re-
quired. Conservative management is indicated on the 
rest of the days. 
- Patients with topical or inhaled steroids: no supple-
menting required.
Other aspects of dental management of these patients are 
(1):
1.Conducting treatment in the morning.
2. Control of anxiety and emotional stress.
3. Use long-acting anesthetics.
4. Treatment of postoperative pain.
5. Prevention of iatrogenic fracture during surgery in pa-
tients with a long history of continuous corticotherapy, 
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because glucocorticoids can increase the risk of fracture 
by causing osteoporosis.
6. Consideration is also required of the possible interac-
tions of glucocorticoids with a other drugs:
- Phenytoin, barbiturates and rifampicin accelerate glu-
cocorticoid metabolism.
- Prednisone bioavailability decreases with the admi-
nistration of antacids.
- Glucocorticoids increase the requirements of insuline, 
oral antidiabetic drugs and hypotensive medication.
Addisonian Crises• 
Addisonian crises or acute adrenococortical insufficien-
cy is a rare but serious complication in patients with 
primary Addison’s disease. Although, actually it is more 
likely to be attributable to secondary adrenal failure 
(administration of high-doses of exogenous corticos-
teroids therapeutically) than to Addison’s disease. The 
reason for this is the sudden withdrawal of exogenous 
corticoids, or the existence of situations requiring grea-
ter amounts of corticoids than those afforded by repla-
cement therapy. It presents as a sudden failure of the 
adrenal cortex function. The resulting clinical picture 
compromises shock with nausea, vomiting, abdominal 
pain and hypotension. Fever and hypothermia may be 
observed and can lead to coma and death (1). 
Dental management of the patient with Addisonian • 
crises
Prevention is the best management approach for Addiso-
nian crises. We should perform a detailed clinical history 
and a consultation with the specialist is recommended, 
and we take action accordingly. However, if crisis takes 
place, we should interrupt dental procedure, place the 
patient in dorsal decubitus and contact with the corres-
ponding medical emergency service. Until medical help 
arrives, the patient should be administered oxygen (5-10 
liters/min). If the patient is unconscious, he should be 
placed in dorsal decubitus with the legs raised, and we 
should notify the emergency service to arrange transfer 
of the patient to the hospital. Before four minutes have 
elapsed, basic vital support should be provided in ac-
cordance to the patient’s condition. If an adrenal cause 
is suspected, 100 mg of hydrocortisone should be ad-
ministered intravenously or intramuscularly, within 30 
seconds if possible, and two hours later, another 100 mg 
of hydrocortisone dissolved in saline for intravenous or 
intramuscular injection should be provided (1).
Hyperadrenocorticism (Cushing’s syndrome)• 
Cushing’s syndrome (CS) refers to manifestations in-
duced by chronic exposure to excess glucocorticoids 
produced by the adrenal cortex. This excess can be cau-
sed by various reasons. It most commonly arises from 
iatrogenic causes (due to administration of exogenous 
glucocorticoids). The second most common cause is a 
high production of ACTH as a result, in most cases, of 
the presence of a pituitary corticotroph adenoma or less 
frequently by an extrapituitary tumor or very rarely by a 
tumor secreting CRH. (18,19).
CS is suspected in the presence of central obesity with 
supraclavicular fat accumulation and a cervical fat pad, 
moon face, thinned skin, acne and hirsutism. Hyperten-
sion, glucose intolerance, menstrual irregularity, osteo-
porosis and pathological fractures, delayed healing,
increased risk of infection and neuropsychological dis-
turbances including depression, emotional irritability, 
sleep disturbances and cognitive deficits are also obser-
ved. Purple striae and muscular atrophy are particularly 
positive stigmata in adults, whereas in child growth re-
tardation are frequently present (18,19).
Dental management of the patient with hyperadre-• 
nocorticism
Dental management in these patients consists in preven-
tion of infections, pathological fractures during surgical 
treatments and complications such as hypertension, hy-
perglycemia, depression and delayed healing. In patients 
on steroids we must evaluate the need to administer 
additional corticosteroids. 
Discussion
1. More common oral manifestations in patients with 
endocrine disorders are:
- Thyroid glands: in hyperthyroidism: accelerated den-
tal eruption, osteoporosis, enlargement of extraglandular 
thyroid tissue, caries and periodontal disease, burning 
mouth syndrome and development of connective-tissue. 
In hypothyroidism: delayed eruption, enamel hypopla-
sia, micrognathia, open bite, macroglossia, thick lips, 
dysgeusia and mouth breathing. 
- Parathyroid glands:  in HPT: brown tumor, loss of 
bone density, soft tissue calcification  and dental abnor-
malities; in hypoparathyroidism:  dental abnormalities, 
a delay or cessation of dental growth and development, 
paresthesia of the tongue or lips and alteration of the fa-
cial muscles.
- Adrenal glands: in Addison’s disease: black-bluish 
plaques in buccal mucosa. 
2. Dental management of patients with endocrine disor-
ders: 
- Thyroid glands: in hyperthyroidism: We must restrict 
the use of adrenaline and avoid severe stress situations 
and the spread of infectious foci. In patients treated with 
propylthiouracil, a complete blood count is usually re-
commended. NSAIDs and aspirin should be used with 
caution. Treatment should be discontinued if signs or 
symptoms of a thyrotoxic crisis develop; in hypothyroi-
dism: a complete blood count before performing dental 
treatment is recommended. We must restrict the use of 
adrenaline and avoid oral infection and central nervous 
depressant drugs. We should know the drug interactions 
of 1-thyroxine. If myxedematous coma develops, we 
will only carry out emergency dental treatment. 
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- Parathyroid glands: in HPT: there is a higher risk of 
bone fracture; in hypothyroidism: control the develop-
ment of caries. 
- Adrenal glands:  in Addison’s disease: We must con-
duct treatment in the morning and control of anxiety. In 
patients with corticotherapy, we must evaluate the ne-
cessity to administer additional corticosteroids; in Addi-
sonian crises: we should interrupt dental procedure; in 
hyperadrenocorcism: we must prevent infection and pa-
thological fractures, and we must evaluate the necessity 
to administer additional corticosteroids. 
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